Current status of molecular-targeted drugs for endometrial cancer (Review).
Current status of molecular-targeted drugs for endometrial cancer (Review).
复制标题
DOI：
10.3892/mco.2013.140
复制
发表时间：
2013-09
影响因子：
1.2
通讯作者：
Aoki D
中科院分区：
文献类型：
--
作者：
Nogami Y;Banno K;Kisu I;Yanokura M;Umene K;Masuda K;Kobayashi Y;Yamagami W;Nomura H;Tominaga E;Susumu N;Aoki D
子宫内膜癌是西方国家常见的妇科恶性肿瘤，在亚洲发病率也呈上升趋势。子宫内膜和信号系统中与恶性肿瘤的发生和发展相关的遗传异常已经被发现，子宫内膜癌的发生机制正在被阐明。与这些异常相关的分子的鉴定导致了使用分子靶向药物治疗子宫内膜癌的新潜在治疗方案。目前子宫内膜癌的化疗经常引起全身副作用，需要停止治疗。此外，罕见组织学类型的癌症的治疗方案尚未建立。最近对子宫内膜癌的研究揭示了不同组织学类型的遗传疾病模式。病理变化背后的遗传和分子信息以及与DNA错配修复基因和表观遗传调控相关的信息也被确定。用分子靶向药物靶向这些机制，目的是在分子和遗传水平上将治疗与致癌机制联系起来。然而，单药治疗的有效率普遍较低，一些问题仍未解决。为了克服这些困难，需要对分子靶向药物与现有治疗方法的组合进行试验，并确定决定敏感性的因素。
Endometrial cancer is a common gynecological malignant tumor in Western countries and its incidence has also been on the increase in Asia. Genetic abnormalities related to onset and progression of malignancy in the endometrial membrane and signaling system have been identified and the developmental mechanism of endometrial cancer is becoming elucidated. The identification of the molecules related to these abnormalities has led to new potential treatment regimens for endometrial cancer, using molecular-targeted drugs. The current chemotherapy for endometrial cancer often causes systemic side effects that require discontinuation of the treatment. Furthermore, a treatment regimen for cancers of rare histological types has not been established. Recent studies on endometrial cancer revealed patterns of genetic disorders that differ among the histological types. Genetic and molecular information that underlie pathological changes and is associated with DNA mismatch repair genes and epigenetic regulation was also identified. Targeting of these mechanisms with molecular-targeted drugs has been performed with the aim of linking treatment to the carcinogenic mechanism at the molecular and genetic levels. However, the response rates with single-agent therapy are generally low and several problems remain unresolved. Trials of combinations of molecular-targeted drugs with currently available treatments and identification of factors determining sensitivity are required to overcome these difficulties.